Age modifies the Retatrutide response, but does not diminish it
1 mg dose group : Mean weight reduction of approximately 8.7%
O texto alerta que verses no aprovadas de agonistas como semaglutida, tirzepatida e retatrutida no so avaliadas quanto a segurana, eficcia e qualidade, devendo ser evitadas Disponvel em: SURMOUNT3/SURMOUNT4 Trial Results
[1] Semaglutide benefits from extensive clinical experience, long-term safety data, and full regulatory approval, whereas Retatrutide remains investigational, with only Phase 2 data
DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P
The single key differentiator is receptor count: retatrutide's third receptor (glucagon) raises the efficacy ceiling but demands slower titration, while semaglutide and tirzepatide trade a lower ceiling for MHRA authorisation and deeper safety data